



# Sleep Disorders

Dr.Niayesh Mohebbi  
Associate Professor of Clinical Pharmacy  
Clinical Pharmacy Department  
Tehran University of Medical Sciences

# Introduction




- Approximately **one-third** of the adult life is expended on sleep.
- Sleep deficiency, including **insufficient sleep duration, irregular timing of sleep, poor sleep quality, and sleep or circadian rhythm disorders**, is highly prevalent and threaten public safety.
- Major sleep disorders include **insomnia ranging from 15 % to 35%**, sleep apnea at 6% to 24% periodic limb movements in sleep (PLMS), and restless leg syndrome (RLS) ranging from 3% to 15%, and narcolepsy at 0.025% to 0.05%.
- **Nightmares, nocturnal leg cramps, and snoring** are more benign sleep disorders.

# Circadian Rhythm and Sleep Cycles

- Sleep is a **dynamic process** with a cyclical recurrence and varying stages. The endogenous sleep-wake pattern of humans is based on the solar day-night cycle called the **circadian rhythm**.
- Circadian rhythm is controlled both by **internal and external factors**. Sensory input (**visual and acoustic**) or other external factors modify the "**internal clock**" to a **24 hour** day through working with the internal network and signaling brain centers to either wake or sleep.
- Thus, **darkness is a visual cue that prepares the brain for sleep**. Similarly, bright light serves to prepare the brain for wakefulness.

## Sleep duration recommendations by age from the National Sleep Foundation\*



\* These recommendations are very similar, but not identical to those from the American Academy of Sleep Medicine (AASM).<sup>[1,2]</sup>

1. Paruthi S, Brooks LJ, D'Ambrosio C, et al. Recommended amount of sleep for pediatric populations: A statement of the American Academy of Sleep Medicine. *J Clin Sleep Med* 2016; 12:785.

2. Consensus Conference Panel, Watson NF, Badr MS, et al. Recommended amount of sleep for a healthy adult: A Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society. *J Clin Sleep Med* 2015; 11:591.

Republished with permission of National Sleep Foundation, 2016; permission conveyed through Copyright Clearance Center, Inc.

# Circadian Rhythm and Sleep Cycles

- Once sleep is initiated, it alternates between the two phases of **rapid eye movement (REM)** and **non-rapid eye movement (NREM) sleep**.
- These phases vary in length throughout the sleep cycles.
- During a normal night of sleep, a person generally has **four to six cycles** of sleep which last an **average of 90 minutes** (vary 70-120 minutes).

# The Sleep Stages

- Each sleep stage serves a physiologic function and can be monitored in sleep laboratories by polysomnography.
- **Polysomnography** is the term used to describe three electrophysiologic measures: the **electroencephalogram (EEG)**, the **electromyogram**, and the **electro-oculogram**.



# Non-Rapid Eye Movement Sleep

- NREM sleep → 4 stages
- Stage 1 is a transition between sleep and wakefulness known as “*relaxed wakefulness*”, which generally makes up approximately 2% to 5% of sleep.
- Approximately 50% of total sleep time is spent in stage 2, which is rapid-wave (alpha) or lighter sleep.
- Stages 3 and 4 are slow-wave (delta) or deep sleep. Stage 3 occupies an average of 5% of sleep time, whereas stage 4 constitutes 10% to 15% of sleep time in young, healthy adults.



# Non-Rapid Eye Movement Sleep

- At sleep onset, the brain quickly passes through stage 1 and moves to stage 2.
- Muscle activity shuts down, and brain waves become less active.
- After a brief REM period, the brain moves into slow-wave sleep (NREM stages 3 and 4) approximately 1 to 3 hours after a person falls asleep.
- The body continually moves through all of the sleep stages over the course of the night.
- REM periods become longer, and deep sleep lessens during the last half of the night.







Relaxed / Waking



Stage 1 Light Sleep




Stage 2 Light Sleep



Deep Sleep



REM / Dreaming




# Non-Rapid Eye Movement Sleep

- The function of **stage 1** is to initiate sleep.
- **Stage 2** provides rest for the muscles and brain through muscle atonia and low voltage brain wave activity.
- **Arousability from sleep is highest during stages 1 and 2.**
- In contrast, it is **difficult to awaken someone during stages 3 and 4, or delta sleep.** Delta sleep, also known as *restorative sleep*, is enhanced by **serotonin, adenosine, cholecystokinin, and IL-1.**

# Non-Rapid Eye Movement Sleep

- Deep sleep is most abundant in infants and children and tends to level off at approximately 4 hours a night during adolescence.
- At age 65, deep sleep accounts for only 10% of sleep, and at age 75, it often is nonexistent.



**FIGURE 81-1** Normal sleep cycles.

# Rapid Eye Movement Sleep


- REM sleep is also called paradoxical sleep because it has aspects of both deep sleep and light sleep.
- Body and brainstem functions appear to be in a deep sleep state as muscle and sympathetic tone drop dramatically.
- In contrast, neurochemical processes and higher cortical brain function appear active.
- Dreaming is associated closely with REM sleep, and when a person is awakened from REM, alertness returns relatively quickly.

# Rapid Eye Movement Sleep

- Breathing is irregular, (sudden changes in respiratory amplitude and frequency).
- Variability in heart rate, blood pressure (BP), cerebral blood flow, and metabolism
- REM periods cycle approximately every 90 minutes.
- Duration of REM increases in the last half of the night.



## BENEFITS OF SLEEP AND POTENTIAL CONSEQUENCES OF DEPRIVATION




### Delta sleep

- ❖ Essential for restoration and repair of body tissues
- ❖ Secretion of growth hormone

### Consequences of deprivation

- ❖ Musculoskeletal tenderness
- ❖ Increased sensitivity to pain



### REM sleep

- ❖ Essential for brain restoration and growth
- ❖ Memory, creativity, emotional balance, mood, sexuality
- ❖ Psychophysiology growth and personality development

### Consequences of deprivation

- ❖ Agitation and aggression

### REFERENCES

Billiard M. Sleep. Physiology, investigations and medicine. Springer US publishing, 2003




# Insomnia




- During the course of a year, **approximately one-third (30%-36%)** of the population will experience insomnia, and **10% to 15 % will consider the problem severe due to daytime consequences.**
- Decades of scientific findings associate sleep deficiency with increased disease risk, including **cardiovascular and metabolic disease, psychiatric illness, substance abuse, pregnancy complications, and neurobehavioral and cognitive impairment.**
- Insomnia and excessive daytime sleepiness (EDS) in the elderly are leading predictors of **institutionalization.**




## EPIDEMIOLOGY




The most common health complaint



The incidence increases  
with age



Sleep maintenance  
particularly problematic in  
people >65 years



# Diagnosis



- To meet the criteria for insomnia disorder according to **ICSD-3** and **DSM 5**, the sleep disturbance must cause **significant distress or impairment in important areas of functioning** (i.e., social, occupational, educational, academic, behavioral) and occur **at least three nights per week over a 3-month period despite adequate opportunity for sleep.**
- The insomnia disorder can be further classified based on duration as follows:
  - **Episodic (1-3 months)**
  - **Persistent (>3 months)**
  - **Recurrent (two or more episodes in 1 year)**
- Insomnia with duration **less than 1 month**, previously referred to as **transient insomnia**, would be classified as "**other specified insomnia disorder.**"

# Definitions



- **Difficulty Falling Asleep:** Requiring longer than 30 min to fall asleep
- **Difficulty Maintaining Sleep:** Awakenings throughout the night without immediate return to sleep
- **Early-morning awakening:** At least 30 minutes prior to the desired time
- Total sleep time decreased to less than 6 hours



**Are You a  
Healthy  
Sleeper?**



# Patient Assessment



- First determine whether the sleep problem is:
  - Difficulty falling asleep
  - Difficulty maintaining sleep
  - Early-morning awakening
  - Poor-quality sleep
  - Excessive day-time sleepiness (EDS)
- Answers to the questions, “How long does it take you to fall asleep, and how many hours do you sleep?”
- Questions such as “How do you feel during the day: well rested, sleepy, or something else?” can help assess functional impairment.
- **Not all patients need the same amount of sleep.** Approximately 7 to 9 hours of sleep is optimal for most people.

# Patient Assessment



- The next step in patient assessment involves investigating the **possible causes** of the sleep disorder and **any concomitant conditions**.
- **All medical, psychiatric, drug, environmental, and social causes** must be considered and treated along with the sleep disorder.
- **The degree of functional impairment** should be assessed to evaluate the severity of the disorder.



# Etiology of Insomnia



## Drug Induced

- Alcohol
- Bupropion
- SSRI's
- MAOI's
- Thyroid Supplements
- Decongestants
- Appetite Suppressants
- Theophylline
- Corticosteroids
- Dopamine Agonists
- Ca<sup>2+</sup> Channel Blockers
- Diuretics

# Etiology of Insomnia



## Situational

- **Financial Stress**
- **Occupational Stress**
- **Major Life Events**
- **Jet Lag**
- **Shift Work**

## Psychiatric

- **Mood Disorders**
- **Anxiety Disorders**
- **Psychotic Disorders**
- **Substance Abuse**

# Etiology of Insomnia



## Medical

- **Cardiovascular**
- **Respiratory**
- **Chronic Pain**
- **Gastrointestinal**
- **Neurological**
- **Arthritis**
- **Cancer**
- **Endocrine Disorders**
- **Pregnancy**

# Setting Treatment Expectations

- When patients seek treatment for insomnia, it is important that **appropriate expectations** are set.
- Unlike what many patients expect, **normal sleep is NOT immediate unconsciousness that lasts 8 hours** without interruption every night.
- Rather, normal sleep is more appropriately viewed as some nights when sleep latency is **a little longer**, some nights with **occasional interruptions** in sleep, and some nights of **5, 6, or 7 hours** rather than 8 hours of sleep.
- Attempts to treat sleep complaints will fail unless the patient understands that normal sleep means **a return to a pattern of natural variations in sleep**.

# Insomnia Treatment Modalities

- Nonpharmacologic treatments
- Pharmacologic treatments



## BEHAVIORAL STRATEGIES



### Sleep hygiene

- ❖ Good sleeping habits
- ❖ Keeping a regular schedule, exercising, and avoiding naps



### Stimulus control

- ❖ Form a positive and clear association between bed and sleep
- ❖ Establishes a stable sleep-wake schedule



### Sleep restriction

- ❖ Limit time in bed to total sleep time



### Cognitive behavioral therapy – insomnia (CBT-I)

- ❖ A combination of cognitive therapy and behavioral treatments
- ❖ To change unrealistic expectations and negative thoughts about sleep

# Nonpharmacologic Treatment

- The first-line treatment for chronic insomnia should be psychological and behavioral therapies.
- Cognitive-behavioral therapies (CBTs) are effective, long-lasting interventions for insomnia and considered the standard of care.
- They may be more effective than pharmacotherapy for sleep onset latency and sleep efficiency.
- The sleep benefits of these interventions are not immediate and can take several weeks to successfully implement.



# Behavioral Therapy



- **Sleep hygiene**
- **Stimulus control**
- **Relaxation**
- **Sleep Restriction therapy**
- **Cognitive behavioral therapy (CBT)**

# Sleep Hygiene



- Sleep as long as necessary to feel rested and then get out of bed
- Keep a regular sleep schedule (e.g. a wake-up time in the morning)
- Try not to force sleep
- Avoid caffeinated beverages after lunch
- Avoid alcohol near bedtime (eg, late afternoon and evening)
- Avoid smoking or other nicotine intake, particularly during the evening
- Adjust the bedroom environment as needed to decrease stimuli
- Avoid prolonged use of light-emitting screens before bedtime
- Resolve concerns or worries before bedtime
- Exercise regularly, preferably more than four hours prior to bedtime
- Do not go to bed hungry

## Stimulus control therapy rules

1. Go to bed only when sleepy.
2. Do not watch television, read, eat, or worry while in bed. Use bed only for sleep and sex.
3. Get out of bed if unable to fall asleep within 20 minutes and go to another room. Return to bed only when sleepy. Repeat this step as many times as necessary throughout the night.
4. Set an alarm clock to wake up at a fixed time each morning, including weekends.
5. Do not take a nap during the day.

---

*Data from: Bootzin RR, Perlis ML. Nonpharmacologic treatments of insomnia. J Clin Psychiatry 1992; 53:37.*

UpToDate®

## Sleep restriction rules

1. Determine the patient's average sleep time from a sleep diary.
2. Use this average sleep time as the new time allowed in bed each night.
3. Set a consistent wake time based upon the type of insomnia and patient need.
4. Have patient avoid daytime naps.
5. If sleep efficiency increases above 90 percent (85 percent for patients over 65 years of age), then increase time in bed by 15 to 30 minutes.
6. If sleep efficiency decreases below 85 percent (80 percent for patients over 65 years of age), then decrease time in bed by 15 to 30 minutes.

*Adapted from: Spielman AJ, Yang CM, Glovinsky PB. Insomnia: Sleep restriction therapy. In: Insomnia Diagnosis and Treatment, Sateia MJ, Buysse DJ (Eds), Informa UK Ltd, London 2010.*

UpToDate®

# Pharmacologic Treatment

- Pharmacotherapy is indicated for a variety of reasons, including when:
  - **Nondrug interventions fail** or cannot be implemented
  - Sleep disturbances produce significant distress or impairment and **immediate symptom relief is required**
  - **Patient preference** is for drug therapy
  - **Insomnia is comorbid** with another medical, sleep, or psychiatric disorder
- Combination therapy involves initially prescribing both **CBT and a medication (usually for four to eight weeks)**, then tapering the medication off or to an **as-needed schedule** while continuing CBT.

# Ideal Hypnotic



- Has a rapid onset of effect (within 20 minutes)
- Helps the patient sleep throughout the night
- Does not cause daytime impairment
- Carries no abuse potential
- Currently, there are **NO ideal hypnotics.**

# Pharmacologic Treatment



- Available agents vary in **onset, duration, and potential for daytime impairment**, mostly because of their individual pharmacokinetic profiles.
- The selection of an appropriate hypnotic should consider the **type of insomnia** to be treated and the **physiologic characteristics of the patient**.
- For example, if someone cannot fall asleep but has no trouble staying asleep and wants to prevent next-day carryover effects, a rapid-acting hypnotic with short half-life and no active metabolites is desirable.
- **Age, sex, socioeconomic status, and comorbidities** also influence the hypnotic prescribed.



# Drug Classes



- **Benzodiazepines (Triazolam, Estazolam, Temazepam, Lorazepam, Quazepam, Flurazepam)**
- **Nonbenzodiazepine BDZ receptor agonists (Z-drugs) (Zaleplon, Zolpidem, Eszopiclone)**
- **Melatonin agonists (Ramelteon)**
- **Orexin receptor antagonists (Suvorexant)**
- **Other medications:**
  - Antidepressants (Doxepin, Trazodone, Mirtazapine, ...)
  - Diphenhydramine
  - Antipsychotics
  - Barbiturates
  - Over-the-counter (Herbal products, Melatonin, ...)

# Choice of an agent



- **DFS: sleep onset insomnia** a short-acting medication: zaleplon, zolpidem, triazolam, lorazepam, and ramelteon
- **DMS: sleep maintenance insomnia**, a longer-acting medication : zolpidem extended release, eszopiclone, temazepam, estazolam, low dose doxepin, and suvorexant: risk for hangover sedation.

# Choice of an agent



- **Awakening in the middle of the night**, zaleplon and a specific sublingual tablet form of zolpidem, at least **4 hrs** of time in bed remaining after administration
- **History of alcohol or recreational drug dependence**, non-controlled medications such as ramelteon, doxepin, antidepressant or anticonvulsants

# Choice of an agent



- **Consider drug interactions:** sertraline/zolpidem, fluoxetine/zolpidem, fluvoxamine/ramelteon, doxepin/ramelteon
- Medications should ideally be used for **no longer than 4-5 weeks**
- **R/O Secondary causes of insomnia** such as depression, pain, BPH, substance abuse disorders and other sleep disorders

# Benzodiazepines



- Benzodiazepines are a class of sleep promoting medications that bind to **several gamma-aminobutyric acid (GABA) type A receptor subtypes**.
  - Reducing the time to the onset of sleep
  - **Prolonging stage 2 sleep**
  - Prolonging total sleep time
  - **Reducing the relative amount of REM sleep**
- In addition, they **decrease anxiety, impair memory**, and have **anticonvulsive properties**.

# Benzodiazepines



- Benzodiazepines commonly used for the treatment of insomnia include **triazolam, estazolam, lorazepam, temazepam, flurazepam, and quazepam.**
  - Triazolam is **short acting.**
  - Estazolam, lorazepam, and temazepam are **intermediate acting.**
  - Flurazepam and quazepam are **long acting.**
- Benzodiazepines **decrease sleep latency and the number of awakenings, while improving sleep duration and sleep quality.**

# Adverse Effects of Benzodiazepines

- The most common adverse effects associated with the benzodiazepines and nonbenzodiazepines are residual daytime sedation, drowsiness, dizziness, lightheadedness, cognitive impairment, motor incoordination, and dependence.
- In addition, most hypnotics are respiratory suppressants that can worsen obstructive sleep apnea (OSA) or hypoventilation.
- Risks are increased if hypnotics are combined with other central nervous system depressant drugs or alcohol.

# Adverse Effects of Benzodiazepines

- **Long-term use of hypnotics** may be **habit forming**, and **rebound insomnia** may occur when some **short-acting medications** are discontinued.
- Less common adverse effects include **complex sleep-related behaviors** (eg, sleep walking, driving, making telephone calls, eating, or having sex while not fully awake), **anterograde amnesia** (particularly when used with alcohol), **aggressive behavior**, and **severe allergic reaction**.
- **Lethal overdose** is possible, particularly with **concurrent use of alcohol** or another **central nervous system depressant**.



# Adverse Effects of Benzodiazepines

- **Physiologic dependence** on BZDs resulting in a **withdrawal and abstinence syndrome**, develops usually **after 2 to 4 months of daily** use of the longer half-life BZDs.
- **Shorter half-life BZD** use can result in physiologic dependence **earlier (days to weeks)** and may be associated with **more severe** withdrawal problems.
- In 2007 the US FDA issued a **black-box warning** that applies to all medications marketed for insomnia: **angioedema, allergic reaction, complex sleep behaviors.**

# Nonbenzodiazepines (Z-drugs)

- NBRAs have varying degrees of selectivity for the **alpha-1-subunit** on the GABA-A receptor.
- This selectivity imparts hypnotic efficacy with **NO significant anxiolytic, muscle relaxant, or anticonvulsant effects.**
- Nonbenzodiazepines appear to **improve both subjective and objective sleep** outcomes.

# Nonbenzodiazepines (Z-drugs)

- Nonbenzodiazepines **decrease sleep latency** and the **number of awakenings**, while **improving sleep duration and sleep quality**.
- Consequently, NBRAs have a **lower risk of abuse, withdrawal, and tolerance** compared with older nonselective benzodiazepines such as triazolam and temazepam.
- Also they have **fewer reports of rebound insomnia** and **anterograde amnesia** at recommended doses.

# Nonbenzodiazepines (Z-drugs)

- Another potential advantage of NBRAs alpha-1-subunit selectivity is little to NO change in sleep architecture or sleep stages.
- Benzodiazepines increase the percentage of stage 2 sleep but can suppress REM and stage 3 and 4 deep restorative sleep.
- In contrast, **NBRAs** do not interfere with these sleep stages and have **lower rates of uncomfortable REM rebound** (vivid dreams, increased autonomic instability) on discontinuation.

# Nonbenzodiazepines (Z-drugs)

- These attributes make **NBRAs more desirable** for the treatment of chronic insomnia.
- Both **zolpidem controlled-release** and **eszopiclone** are FDA-approved for chronic insomnia and are effective for **up to 6 months of therapy**.

# Nonbenzodiazepines (Z-drugs)

- Nonbenzodiazepines commonly used to treat insomnia include **zaleplon, zolpidem, eszopiclone**, and **zolpidem extended release**.
- The NBRA's differ with respect to **pharmacokinetics** and adverse events.
- Zolpidem, the first NBRA, was marketed in the United States in 1991 .

# Zolpidem



- **Zolpidem immediate release** – Zolpidem has a half-life of approximately 1.4 to 4.5 hours.
- It is indicated for the **short-term treatment of insomnia** characterized by **difficulty with sleep initiation**.
- Zolpidem is not approved for long-term use (**NO more than 4 weeks**).

# Zolpidem



- For faster sleep onset, **zolpidem should be taken on an empty stomach** for faster absorption.
- A food-effect study demonstrated that administration of a zolpidem 10 mg tablet 20 minutes after a meal resulted in a decrease in AUC and C<sub>max</sub> of 15 % and 25%, respectively, and an increase in the T<sub>max</sub> from 1.4 to 2.2 hours.
- Zolpidem is metabolized by the **oxidative cytochrome P-450 isoenzyme CYP3A4**; therefore, drug interactions should be considered when zolpidem is coadministered with **CYP3A4 inhibitors such as diltiazem or fluoxetine**.



# Zolpidem



- Zolpidem has **NO active metabolites**, and it has a **low risk of residual daytime sedation** in recommended doses.
- Also, gender metabolism differences exist where **women metabolize zolpidem slower than men**, resulting in **blood levels nearly two-fold higher**.
- As a result, **in women or the elderly**, the recommended starting dose is **5 mg zolpidem** immediate-release.

# Zolpidem



- **Zolpidem extended release** – Zolpidem extended release has a half-life of about 1.4 to 4 hours, but is **released over a longer duration.**
- It was developed to **improve both sleep onset insomnia** and **sleep maintenance insomnia.**
- Zolpidem extended release is **NOT limited to short-term use** and there is little evidence for abuse or dependence in most patients.

# Zaleplon



- **Zaleplon** – Zaleplon has a **very short half-life of about one hour**. As a result, it is effective for patients who have **difficulty falling asleep** (ie, sleep onset insomnia), but **may NOT be effective for patients who have difficulty maintaining sleep** (ie, sleep maintenance insomnia).
- Due to the very short half-life, the **potential for hangover sleepiness is minimal** after normal sleep periods.
- **It can be taken in the middle of the night** as long as the **individual has 4 hours left in bed**.
- Zaleplon is metabolized **primarily via aldehyde oxidase**, CYP3A4 is a secondary route of metabolism, and there are no active metabolites.
- Zaleplon is not indicated for long-term use (**NO more than 4 weeks**).

# Eszopiclone



- **Eszopiclone** – Eszopiclone has the **longest half-life** of the approved nonbenzodiazepines, approximately six hours.
- Eszopiclone is effective for both **sleep onset insomnia** and **sleep maintenance insomnia**.
- Eszopiclone has **less receptor selectivity** than either zaleplon or zolpidem, potentially resulting in some **anxiolytic, amnestic, and anticonvulsant activity**.
- Eszopiclone is **primarily metabolized by CYP3A4**, so drugs that induce or inhibit this isoenzyme can have an impact on metabolism and a clinical effect.

# Eszopiclone



- Patients taking eszopiclone may report an **unpleasant metallic taste**.
- Eszopiclone is **NOT limited to short-term use** and there is little evidence for abuse or dependence in most patients.
- Eszopiclone maintains efficacy with no evidence of tolerance after **6 months of continuous use, resulting in FDA approval for long-term use**.

# Adverse Effects of Z-drugs

- The adverse effects of nonbenzodiazepine hypnotics are **generally similar** to those associated with the benzodiazepines.
- Common possible adverse effects include **headache** (30%), **abdominal pain** (6%), **asthenia** (5%), **somnolence** (5%), **dizziness** (7%), and **GI disturbances** (2%).
- **Hallucinations, mostly visual**, are more common in **elderly** patients, those taking **high doses**.
- Another rare allergic reaction is **facial swelling (angioedema)**. **All manufacturers of hypnotic medication** are required to include this information in their package inserts.

# Adverse Effects of Z-drugs

- **Tolerance and withdrawal** associated with NBRAs is **unlikely** but reported with abrupt discontinuation and patients should be counseled of this possibility, particularly at high doses.
- **Complex sleep-related behaviors**, including sleepwalking, sleep driving, eating, and other behaviors performed while not fully awake, can occur in patients taking nonbenzodiazepines.
- These events appear to be more common with zolpidem, zaleplon, and eszopiclone than other medications used for sleep.

# Adverse Effects of Z-drugs



- Across studies, estimates for **sleep-related behaviors** of any severity related to nonbenzodiazepine hypnotics range widely, from **3 to 25 percent**.
- **While most events are non-serious**, rare cases of injury and even death have been described.
- **Higher dose appears to be a risk factor** for complex sleep-related behaviors.



# Adverse Effects of Z-drugs



- **In 2019 and by the FDA**, a **boxed warning** on the risk of rare but serious **complex sleep-related behaviors** was added to all formulations of zolpidem, zaleplon, and eszopiclone, along with the following information and guidance:
- These events can occur **with just one dose** of these medicines as well as after a longer duration of treatment.
- These events can occur **without a prior history of such events**.
- Eszopiclone, zaleplon, and zolpidem are **contraindicated in patients who report an episode of complex sleep behavior** after taking these insomnia medicines.

# Adverse Effects of Z-drugs




- Tell patients to **discontinue** their insomnia medicine if they experience an episode of complex sleep behavior even if it did not result in a serious injury.
- When starting patients on eszopiclone, zaleplon, or zolpidem, **follow the dosing recommendations** in the prescribing information and **start with the lowest possible dose.**

# Dosing Precautions of Z-drugs

- There has been increasing recognition that **variability in nonbenzodiazepine metabolism** may affect next-morning drug levels and side effects, especially among **older adults and women**.
- In 2013, the FDA published a safety communication that the recommended dose for **zolpidem be set at the lowest dose (5 mg) for women** and also be considered for men.
- In addition, a new warning was issued for **zolpidem extended release**, advising that individuals **refrain from driving** or other activities that require mental alertness **the day after taking the drug**.

# Orexin receptor antagonists

- Orexin A and orexin B are **hypothalamic neuropeptides**
- **Suvorexant**, an oral dual orexin receptor antagonist with a **12-hour half-life**, was approved by the FDA in August 2014
- **Sleep latency and maintenance**

- 
- **Rebound insomnia** with discontinuation of suvorexant
  - Suvorexant is metabolized by cytochrome P450 3A4 (CYP3A4): potential toxicity with CYP3A4 inhibitors
  - Suvorexant **have not yet been compared directly with other therapies for insomnia**

# Antidepressants



- **Doxepin**, approved by the FDA at doses of 3 and 6 mg primarily for the treatment of insomnia
- **Low** anticholinergic effect in this dose
- Typical antidepressant dosage is **>75 mg**
- **Geriatric patients**  
(sp.with early morning awakenings)

# Doxepin




- Doxepin 3, 6mg improved sleep efficiency during the **final third of the night and in the 7,8<sup>th</sup> hr** of sleep.
- Efficacy demonstrated **up to 3 months**

# Antidepressants (e.g, trazodone)

- Such antidepressants may be useful in the management of patients who have insomnia associated with depression, although they are not approved by the FDA for treatment of insomnia
- *If insomnia is **chronic and resistant to hypnotic treatment***
- low abuse potential



- 
- All antidepressants including SSRIs such as sertraline, can improve sleep as the depression lifts
  - Insomnia related to depression will improve as depressive symptoms improve **in 2-8 weeks**
  - SSRIs (44%), bupropion and MAOIs can all cause insomnia as well
  - **Addition of trazodone or mirtazepine, z-hypnotics**

# Trazodone



- Trazodone is not thought to be a highly effective antidepressant because most people cannot tolerate an effective dose **300-600mg (>150mg)**
- **50-200mg** bedtime to induce sleep while awaiting the onset of primary antidepressant

# Trazodone



- Side Effects:
  - Residual morning sedation
  - Orthostatic hypotension
  - Priapism
  - May produce cognitive or motor impairment
- Insomnia co morbid with **Depression** and **Fibromyalgia**

# Mirtazepin



- **Mirtazepine** 5-HT<sub>2</sub> antagonist, antihistamine effects, safer than TCAs, no priapism, but weight gain!
- NO placebo-controlled randomized clinical trials in primary insomnia
- Insomnia associated with **hot flashes** in premenopausal women, particularly those with a need for weight gain

# TCAs



- TCAs were used to treat primary insomnia for years based on case reports describing efficacy in doses of **10-75 mg/ night**
- TCAs **increase the risk of cardiovascular problems and anticholinergic side effects** in a dose-related manner
- TCAs are **more toxic** in **overdose** when compared with trazodone, and there are multiple reports of TCA plasma levels increasing to toxic levels when administered in **combination** with **sertraline > 100mg/day**

# Antihistamines, Diphenhydramine

- There is little evidence that diphenhydramine improves insomnia and it may cause sedation the next day (due to its long half-life).
- **Routine use** of diphenhydramine to treat insomnia is **not recommended**.
- Doxylamine, hydroxyzine
- Daytime Residual Effects in 50% of Patients, feel slow, lethargic and not mentally sharp. (“Hangover Effect”), Cognitive Impairment
- Tolerance to Sedative effects **after 1-2 Weeks (3-7 days)** of Continued Use

# Antipsychotics




- Few trials , potentially significant **adverse effects** , **abuse potential**
- The Canadian and American Choosing Wisely initiatives, American chronic insomnia guideline **recommend against** the routine use of antipsychotics to treat insomnia in patients without psychosis is not recommended
- Antipsychotics should generally be reserved for cases with **primary psychiatric disorders**



- **Quetiapine and Olanzapine**
- **Mechanism:** Antagonize dopamine, histamine, serotonin, muscarinic, cholinergic and  $\alpha$ 1 receptors
- Decreased sleep latency
- Olanzapine may increase **deeper NREM sleep**
- Quetiapine may reduce REM sleep



- 
- Increase risk of death in dementia
  - Significant potential risks:
    - **Akathisia**
    - **Weight gain**
    - **Orthostatic hypotension**
    - **Metabolic syndrome:** weight gain, glucose intolerance

# Quetiapine



- Antipsychotic dose 15-800 mg but **25-200 mg** for insomnia

# Melatonin



- It may be useful in patients who have **delayed sleep-wake phase syndrome** (a circadian sleep-wake rhythm disorder) and in a subgroup of patients with **low melatonin levels**
- Individuals **older than 50 years of age** and **those traveling eastward** have more difficulty in adjusting
- **0.5-10 mg** before endogenous peak

# Melatonin receptor agonist

- **Ramelteon: 2005 FDA**
- 17 more potent at melatonin type 1 (decreased waking signal) and type 2 (circadian rhythm)
- Primary benefit on sleep latency

# Anticonvulsants




- **Pregabalin, Gabapentin** diminish release of glutamate and norepinephrine
- Gabapentin **100-900mg**
- **Palliative care:** pain related insomnia such as fibromyalgia, peripheral neuropathy, traumatic nerve injury
- Have **not significant abuse potential** and dose not affect hepatic function, so in alcohol withdrawal
- Pregabalin in GAD related insomnia

# Risks and side effects Common to all hypnotics

- Residual daytime sedation, drowsiness, dizziness, lightheadedness, cognitive impairment, motor in coordination, and dependence
- most are **respiratory suppressants** :worsen obstructive sleep apnea or hypoventilation
- In 2007 the US FDA issued a black-box warning that applies to all medications marketed for insomnia: **angioedema, allergic reaction, complex sleep behaviors**

# Adverse effects of benzodiazepines

- Exposure to any BZD was associated with **higher rate of hip fracture**
- Use of short half-life BZDs was found to be **no safer than use of long half-life BZDs**, and the risk of hip fracture was highest during the **first 2 weeks after starting a BZD**

- 
- **AGS:** BZD should be avoided in patients over 65 years
  - Increase risk of cognitive impairment, delirium, falls, fractures, motor vehicle crashes
  - Use of BZD in elderly patients should be avoid (HIGH QUALITY EVIDENCE)
    - with a history of falls
    - Who are already receiving 2 or more drugs that act on the CNS



# Long vs. short acting




- In treatment of “**seizure disorders, rapid eye movement sleep disorders, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and peri-procedural anesthesia,**” **long-acting agents**, such as clonazepam may be appropriate.
- short-acting agents **are more dangerous for falls and fractures**, but because of the decreased metabolism of long-acting benzodiazepines, the use of the latter will leave an elderly patient with residual daytime sleepiness and cognitive impairment

# Adverse effects of nonbenzodiazepines

- In 2013, the FDA recommended dose for zolpidem be set at the **lowest dose (5 mg for all except zolpidem extended release, which is now 6.25 mg) for women**
- Blood levels of zolpidem **above about 50 ng/mL** appeared capable of impairing driving and increase the risk of an accident

# complex sleep-related behaviors

- In 2007, FDA **labeling** of z-hypnotics
- Sleepwalking, eating, driving, sexual behavior
- **NOT taking them with other sedatives, alcohol or sleep restriction**
- **Zolidem is the most often** associated with sleepwalking and the sleep related eating disorder and hallucination(visual)

- 
- **Sedating antidepressants** : sedation, dizziness, cardiac arrhythmias, orthostatic hypotension and potential priapism, weight gain
  - **Antihistaminergic agents** is not recommended
  - **Atypical antipsychotics**: risk of stroke and sudden cardiac death and lack of efficacy data in geriatric

# Herbal Products



- A meta-analysis that included 14 randomized trials in over 1600 patients found **NO significant difference between any herbal medicine and placebo** on any of 13 clinical efficacy measures of insomnia.
- The majority of the trials (11 out of 14) studied **valerian**; **chamomile**, kava, and wuling were studied in one trial each.
- Unlike the other herbals studied, **valerian was associated with a greater number of adverse events** per person compared with placebo. Valerian may also produce **hepatotoxic effects**.

# Thanks for Your Attention

